Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Gavura

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Bioethics|January 26, 2016
Alternative Medicine and the Ethics Of CommerceChris Macdonald, Scott Gavura
Research in Social & Administrative Pharmacy : RSAP|July 2, 2013
Pharmacy 2.0: a scoping review of social media use in pharmacyKelly Grindrod, Andrea Forgione, Ross T Tsuyuki, et al.
JCO Oncology Practice|October 20, 2020
Evolving Best Practice for Take-Home Cancer DrugsAliya Pardhan, Kathy Vu, Daniela Gallo-Hershberg, et al.
Current Oncology (Toronto, Ont.)|March 27, 2024
Comparative Effectiveness and Safety of Trastuzumab Biosimilars to Herceptin for Adjuvant Treatment of HER2+ Breast CancerCaroline Muñoz, Xiaochen Tai, Jessica Arias, et al.
Current Oncology (Toronto, Ont.)|March 3, 2021
Clinician Perspectives of COVID-19-Related Cancer Drug Funding Measures in OntarioRohini D Naipaul, Rebecca E Mercer, Kelvin K W Chan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 27, 2024
Comparative Safety and Effectiveness of Bevacizumab Biosimilars to Originator for the Treatment of Metastatic Colorectal CancerCaroline Muñoz, Jaclyn M Beca, Erind Dvorani, et al.
The Lancet. Oncology|March 28, 2024
Cost and value of cancer medicines in a single-payer public health system in Ontario, Canada: a cross-sectional studyJoseph C Del Paggio, Rohini Naipaul, Scott Gavura, et al.
Cancer|January 9, 2020
Assessing the efficacy-effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeuticsCameron M Phillips, Ambica Parmar, Helen Guo, et al.
BMJ Open|January 10, 2020
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaborationKelvin Chan, Seungree Nam, Bill Evans, et al.
Cancer Medicine|November 19, 2019
Are population-based patient-reported outcomes associated with overall survival in patients with advanced pancreatic cancer?Wei Fang Dai, Jaclyn Beca, Helen Guo, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Bioethics|January 26, 2016
Alternative Medicine and the Ethics Of CommerceChris Macdonald, Scott Gavura
Research in Social & Administrative Pharmacy : RSAP|July 2, 2013
Pharmacy 2.0: a scoping review of social media use in pharmacyKelly Grindrod, Andrea Forgione, Ross T Tsuyuki, et al.
JCO Oncology Practice|October 20, 2020
Evolving Best Practice for Take-Home Cancer DrugsAliya Pardhan, Kathy Vu, Daniela Gallo-Hershberg, et al.
Current Oncology (Toronto, Ont.)|March 27, 2024
Comparative Effectiveness and Safety of Trastuzumab Biosimilars to Herceptin for Adjuvant Treatment of HER2+ Breast CancerCaroline Muñoz, Xiaochen Tai, Jessica Arias, et al.
Current Oncology (Toronto, Ont.)|March 3, 2021
Clinician Perspectives of COVID-19-Related Cancer Drug Funding Measures in OntarioRohini D Naipaul, Rebecca E Mercer, Kelvin K W Chan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 27, 2024
Comparative Safety and Effectiveness of Bevacizumab Biosimilars to Originator for the Treatment of Metastatic Colorectal CancerCaroline Muñoz, Jaclyn M Beca, Erind Dvorani, et al.
The Lancet. Oncology|March 28, 2024
Cost and value of cancer medicines in a single-payer public health system in Ontario, Canada: a cross-sectional studyJoseph C Del Paggio, Rohini Naipaul, Scott Gavura, et al.
Cancer|January 9, 2020
Assessing the efficacy-effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeuticsCameron M Phillips, Ambica Parmar, Helen Guo, et al.
BMJ Open|January 10, 2020
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaborationKelvin Chan, Seungree Nam, Bill Evans, et al.
Cancer Medicine|November 19, 2019
Are population-based patient-reported outcomes associated with overall survival in patients with advanced pancreatic cancer?Wei Fang Dai, Jaclyn Beca, Helen Guo, et al.
Pageof 3